文献速递神经儿科影像CTMR

儿童多形性黄色星形细胞瘤:多中心神经影像与临床相关性研究

Pediatric Pleomorphic Xanthoastrocytomas: A Multicenter Neuroradiologic and Clinical Correlation Study.
PubMed 文献 · AJNR Am J Neuroradiol · 2026-10-22

这项国际多中心回顾性研究纳入63例组织学确诊的儿童多形性黄色星形细胞瘤(PXA),分析神经影像与分子特征(BRAF V600E突变78%、CDKN2A/B缺失93.5%)及临床结局。CNS WHO 3级肿瘤诊断时体积显著大于2级(中位87,920 mm³ vs 14,925 mm³,P=0.03)。全切除与无进展生存改善相关(HR=0.39;95%CI 0.16-0.96;P=0.041),3年总生存率94.7%。

要点

  • MRI上PXA多边界清楚,皮层接触86.0%、软脑膜接触56.4%,常见囊变59.6%,平均ADC 1005×10⁻⁶ mm²/sec。
  • CT上多数肿瘤与灰质等密度(52.0%),3级肿瘤脑积水更常见(71.4% vs 26.3%,P=0.07)。
  • 全切除与无进展生存改善独立相关(HR=0.39;95%CI 0.16-0.96;P=0.041)。

核心结论

  • 儿童PXA具有独特的神经影像与分子特征并与预后相关,影像与临床特征的综合评估对风险分层和个体化治疗策略至关重要。

研究设计与样本

  • 国际多中心回顾性研究,纳入63例组织学确诊的儿童PXA患者,复习神经影像资料并记录分子分析(重点为BRAF V600E突变和CDKN2A/B缺失),采用统计生存模型分析治疗方式与临床结局(包括无进展生存和总生存)。

关键影像表现/征象

  • MRI上PXA通常边界清楚,皮层接触占86.0%,软脑膜接触占56.4%。
  • MRI上囊变常见,占59.6%,平均ADC为1005×10⁻⁶ mm²/sec,呈中等弥散。
  • CT上多数肿瘤与灰质等密度,占52.0%,3级肿瘤脑积水更常见(71.4% vs 26.3%,P=0.07)。

诊断标准与关键数值

  • CNS WHO分级:73.3%为2级,26.7%为3级。
  • 分子特征:BRAF V600E突变见于78%的病例,CDKN2A/B缺失见于93.5%。
  • CNS WHO 3级肿瘤诊断时中位体积为87,920 mm³,2级为14,925 mm³(P=0.03)。
  • 全切除与无进展生存改善相关(HR=0.39;95%CI 0.16-0.96;P=0.041),独立于诊断年龄和肿瘤分级。
  • 肿瘤体积较大与较差的生存结局相关(HR=3.47;95%CI 0.83-14.4;P=0.087),同样独立于肿瘤分级和诊断年龄。

临床应用与阅片要点

  • 阅片时注意评估肿瘤边界、皮层及软脑膜接触、囊变和弥散特征(平均ADC 1005×10⁻⁶ mm²/sec)。
  • CT上注意肿瘤与灰质的密度关系及是否合并脑积水,3级肿瘤脑积水更常见(71.4% vs 26.3%,P=0.07)。
  • 报告中记录肿瘤体积和切除程度,因全切除与无进展生存改善相关(HR=0.39;95%CI 0.16-0.96;P=0.041)。
  • 结合BRAF V600E突变(78%)和CDKN2A/B缺失(93.5%)等分子信息进行综合评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND AND PURPOSE: Pleomorphic xanthoastrocytomas (PXAs) are rare pediatric brain tumors accounting for approximately 1% of primary brain neoplasms in children and young adults. Despite recent imaging and molecular advances, gaps remain in our understanding of their diverse imaging characteristics and clinical outcomes. This study provides a large international, multi-institutional analysis of pediatric PXA, focusing on neuroimaging and clinical outcomes.

MATERIALS AND METHODS: We conducted a retrospective international multicenter study including 63 pediatric patients with histologically confirmed PXAs. Neuroimaging data were reviewed, and molecular analyses were recorded with emphasis on BRAF V600E mutations and CDKN2A/B deletions. Treatment modalities and clinical outcomes, including progression-free and overall survival, were analyzed using statistical survival models.

RESULTS: Of tumors, 73.3% were CNS World Health Organization (WHO) grade 2 and 26.7% were CNS WHO grade 3. The median age at diagnosis was 10.7 years (interquartile range, 6.9 years). CNS WHO grade 3 tumors were significantly larger at diagnosis, with a median volume of 87,920 mm³ compared with 14,925 mm³ for grade 2 tumors (P = .03). BRAF V600E mutations were identified in 78% of cases, and CDKN2A/B deletions in 93.5%. On MRI, PXAs typically appeared well defined, with cortical and leptomeningeal contact (86.0% and 56.4%, respectively), frequent cysts (59.6%), and intermediate diffusivity (mean ADC, 1005 × 10-6 mm2/sec). CT showed that most tumors were isointense to gray matter (52.0%), with hydrocephalus more common in grade 3 tumors (71.4% versus 26.3%, P = .07). Gross total resection was achieved in 73.7% of cases and was associated with improved progression-free survival, independent of age at diagnosis and tumor grade (hazard ratio = 0.39; 95% CI, 0.16-0.96; P = .041). Larger tumor volume correlated with poorer survival outcomes (hazard ratio = 3.47; 95% CI, 0.83-14.4; P =.087), also independent of tumor grade and age at diagnosis. Tumor recurrence occurred in 44.8% of patients at 3 years. The estimated 3-year overall survival rate was 94.7%.

CONCLUSIONS: Pediatric PXAs exhibit distinct neuroimaging and molecular features correlating with prognosis. Integrated evaluation of radiologic and clinical features is critical to improve risk stratification and guide personalized therapeutic strategies in this rare tumor population.

来源:AJNR Am J Neuroradiol,查看原文。版权归原作者所有。

引用

  1. Chhatwal K, Hargreaves T, Pacchiano F, et al. Pediatric Pleomorphic Xanthoastrocytomas: A Multicenter Neuroradiologic and Clinical Correlation Study. AJNR Am J Neuroradiol. 2026. PMID: 41974509. doi:10.3174/ajnr.A9340

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。